ELGN-2112 safety study for very preterm and small babies
Part of Digestive system, Hormones & metabolism clinical trials.
This Phase 2 trial studies whether ELGN-2112 is safe in babies born very early or smaller than expected before birth. It may help doctors understand how to better care for these high-risk newborns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby was born very early: under 26 weeks, or small for gestational age born at 26 to 31 weeks and 6 days
- Your baby weighs at least 450 grams at birth
- The pregnancy was a single baby or twin (not triplets or more)
- Your baby’s sex can be male or female
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether ELGN-2112 helps preterm babies absorb food from the intestines. It aims to improve intestinal malabsorption and check safety.
This trial studies a treatment made from special particles in donor breast milk, given to very early-born babies who are at risk of a serious gut infection called NEC. It aims to see if these particles can help protect their intestines.
This trial is studying a condition called necrotizing enterocolitis in very small or premature babies. It looks for ways to better understand or treat this serious gut problem.
This trial tests whether giving lactase (a natural enzyme that helps digest milk sugar) to preterm babies helps them gain weight better. It is for infants born between 28 and 34 weeks of pregnancy who get most of their nutrition through the gut.
This trial tests if giving lactase enzyme supplements helps preterm babies (born at or before 32 weeks) tolerate their feedings better. If your baby was born early and started feeding within the first few days of life, this study may be a good fit.
This study tests whether an individualized nutrition plan based on weekly measurements can help preterm infants grow better and improve brain development compared to standard feeding. It is for babies born very early (32 weeks or less) who receive human milk.
Hear when a new Intestinal Malabsorption trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.